Gene therapy and metabolic engineering

Metabolic Engineering

Volumn 2, Issue 2, 2000, Pages 126-139

  Wang, Fubao ^a   Raab, R Michael ^a   Washabaugh, Michael W ^a   Buckland, Barry C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CELL DYSFUNCTION; CYSTIC FIBROSIS; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE THERAPY; METABOLIC ENGINEERING;

EID: 0034125943     PISSN: 10967176     EISSN: None     Source Type: Journal    
DOI: 10.1006/mben.1999.0144     Document Type: Article

References (115)

1. Alton E. W. F. W., Stern M., Farley R., Jaffe A., Chadwick S. L., Phillips J., Davies J., Smith S. N., Browning J., Davies M. G., Hodson M. E., Durham S. R., Li D., Jeffery P. K., Scallan M., Balfour R., Eastman S. J., Cheng S. H., Smith A. E., Meeker D., Geddes D. M. P. T. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo-controlled trial. Lancet. 353:1999;947-954.
2. Altschul S. F., Gish W., Miller W., Myers E. W., Lipman D. J. Basic local alignment search tool. J. Mol. Biol. 215:1990;403-410.
3. Anderson W. F. Human gene therapy. Nature (London). 392:1998;A25-A30.
4. Andreadis S. T., Roth C. M., Le Doux J. M., Morgan J. R., Yarmush M. L. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol. Prog. 15:1999;1-11.
5. Antinozzi P. A., Berman H. K., O'Doherty R. M., Newgard C. B. Metabolic engineering with recombinant adenoviruses. Annu. Rev. Nutr. 19:1999;511-544.
6. Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A., Struhl K., Albright L. M., Coen D. M., Varki A. Current Protocols in Molecular Biology. 1998;Wiley, New York. p. 9.10.1-9.10.11.
7. Bachmair A., Finley D., Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science. 234:1986;179-186.
8. Bailey J. E. Toward a science of metabolic engineering. Science. 252:1991;1668-1675.
9. Bailey J. E., Sburlati A., Hatzimanikatis V., Lee K., Renner W. A., Tsai P. S. Inverse metabolic engineering: A strategy for directed genetic engineering of useful phenotypes. Biotechnol. Bioeng. 52:1996;109-121.
10. Beadle G. W., Tatum E. L. Genetic control of biochemical reactions in Neurospora. Proc. Natl. Acad. Sci. USA. 27:1941;499-506.
11. Berns K. I. Parvoviridae: The viruses and their replication. Fields B. N. Fields Virology. 1996;2173-2198 Lippincott-Raven, Philadelphia.
12. Berns K. I., Linden R. M. The cryptic life style of adeno-associated virus. BioEssays. 17:1995;237-245.
13. Blaese R. M. The ADA human gene therapy clinical protocol. Hum. Gene Ther. 1:1990;327-362.
14. Boucher R. C. Current status of CF gene therapy. Trends Genet. 12:1996;81-84.
15. Boucher R. C. Cystic fibrosis. Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L., Hauser S. L., Longo D. L. Harrison's Principles of Internal Medicine. 1998;1448-1451 McGraw-Hill, New York.
16. Boulikas T. Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Anticancer Res. 17:1997;1471-1506.
17. Brown P. O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nature Genet. 21:1999;A33-A37.
18. Burcin M. M., Schiedner G., Kochanek S., Tsai S. Y., O'Malley B. W. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA. 96:1999;355-360.
19. Cakar Z. P., Sauer U., Bailey J. E. Metabolic engineering of yeast: The perils of auxotrophic hosts. Biotechnol. Lett. 21:1999;611-616.
20. Calik P., Ozdamar T. H. Mass flux balance-based model and metabolic engineering analysis for serine alkaline protease synthesis by Bacillus licheniformis. Enzyme Microb. Technol. 24:1999;621-635.
21. Cameron D. C., Altaras N. E., Hoffman M. L., Shaw A. J. Metabolic engineering of propanediol pathways. Biotechnol. Prog. 14:1998;116-125.
22. Carrier T. A., Keasling J. D. Controlling messenger RNA stability in bacteria: Strategies for engineering gene expression. Biotechnol. Prog. 13:1997a;699-708.
23. Carrier T. A., Keasling J. D. Engineering mRNA stability in E. coli by the addition of synthetic hairpins using a 5′ cassette system. Biotechnol. Bioeng. 55:1997b;577-580.
24. Carrier T. A., Keasling J. D. Library of synthetic 5′ secondary structures to manipulate mRNA stability in Escherichia coli. Biotechnol. Prog. 15:1999;58-64.
25. Carrier T. A., Jones K. L., Keasling J. D. mRNA stability and plasmid copy number effects on gene expression from an inducible promoter system. Biotechnol. Bioeng. 59:1998;666-672.
26. Hum. Gene Ther. 9:1998;1513-1524.
27. Cox L. S., Lane D. P. Tumor suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. BioEssays. 17:1995;501-508.
28. Crystal R. G. Transfer of genes to humans: Early lessons and obstacles to success. Science. 270:1995;404-410.
29. Dachs G. U., Dougherty G. J., Stratford I. J., Chaplin D. J. Targeting gene therapy to cancer: A review. Oncol. Res. 9:1997;313-325.
30. Davis S. N., Granner D. K. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. Hardman J. G., Limbird L. E., Molinoff P. B., Ruddon R. W., Goodman-Gilman A. Goodman Gilman's The Pharmacological Basis of Therapeutics. 1995;1487-1517 McGraw-Hill, New York.
31. Delgado J., Liao J. C. Inverse flux analysis for reduction of acetate excretion in Escherichia coli. Biotechnol. Prog. 13:1997;361-367.
32. DeVita V. T., Hellman S., Rosenberg S. A. Biologic Therapy of Cancer. 1994;Lippincott-Raven, Philadelphia.
33. Docherty K. Gene therapy for diabetes mellitus. Clin. Sci. 92:1997;321-330.
34. Eck S. L., Wilson J. M. Gene-based therapy. Hardman J. G., Limbird L. E., Molinoff P. B., Ruddon R. W., Goodman-Gilman A. Goodman Gilman's The Pharmacological Basis of Therapeutics. 1995;77-101 McGraw-Hill, New York.
35. Edwards J. S., Palsson B. O. How will bioinformatics influence metabolic engineering? Biotechnol. Bioeng. 58:1998;162-169.
36. Endy D., Kong D., Yin J. Intracellular kinetics of a growing virus: A genetically structured simulation for bacteriophage T7. Biotechnol. Bioeng. 55:1997;375-389.
37. Felgner P. L., Tsai Y. J., Sukhu L., Wheeler C. J., Manthorne M., Mashall J., Cheng S. H. Improved cationic lipid formulations for in vivo gene therapy. Ann. N.Y. Acad. Sci. 772:1995;126-139.
38. Fenton R. G., Longo D. L. Cell biology of cancer. Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L., Hauser S. L., Longo D. L. Harrison's Principles of Internal Medicine. 1998;505-512 McGraw-Hill, New York.
39. Fisher D. E. Apoptosis in cancer therapy: Crossing the threshold. Cell. 78:1994;539-542.
40. Foster D. W. Diabetes mellitus. Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L., Hauser S. L., Longo D. L. Harrison's Principles of Internal Medicine. 1998;2060-2081 McGraw-Hill, New York.
41. Fussenegger M., Bailey J. E. Molecular regulation of cell-cycle progression and apoptosis in mammalian cells: Implications for biotechnology. Biotechnol. Prog. 14:1998;807-833.
42. Fussenegger M., Schlatter S., Dätwyler D., Mazur X., Bailey J. E. Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells. Nature Biotechnol. 16:1998;468-472.
43. Gage F. H. Cell therapy. Nature (London). 392:1998;A18-A23.
44. Gaines G. L. III. Metabolic observation: NMR spectroscopy of protonated compounds metabolized by deuterated organisms. SIM News. 46:1996;283-290.
45. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89:1992;5547-5551.
46. Gossen M., Bonin A. L., Bujard H. Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements. Trends Biochem. Sci. 18:1993;471-475.
47. Gossen M., Bonin A. L., Freundlieb S., Bujard H. Inducible gene expression systems for higher eukaryotic cells. Curr. Opin. Biotechnol. 5:1994;516-520.
48. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 268:1995;1766-1769.
49. Griffiths A. J. F., Miller J. H., Suzuki D. T., Lewontin R. C., Gelbart W. M. An Introduction to Genetic Analysis. 1996;Freeman, New York. p. 480-482.
50. Gygi S. P., Rochon Y., Franza B. R., Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19:1999;1720-1730.
51. Hall S. J., Chen S.-H., Woo S. L. C. The promise and reality of cancer gene therapy. Am. J. Hum. Genet. 61:1997;785-789.
52. Harding T. C., Geddes B. J., Murphy D., Knight D., Uney J. B. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nature Biotechnol. 16:1998;553-555.
53. Harvey D. M., Caskey C. T. Inducible control of gene expression: Prospects for gene therapy. Curr. Opin. Chem. Biol. 2:1998;512-518.
54. Hatzimanikatis V., Choe L. H., Lee K. H. Proteomics: Theoretical and experimental considerations. Biotechnol. Prog. 15:1999;312-318.
55. Heinrich R., Rapoport T. A. A linear steady-state treatment of enzymatic chains, general properties, control and effector strength. Eur. J. Biochem. 42:1974;89-95.
56. Hofmann A., Nolan G. P., Blau H. M. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc. Natl. Acad. Sci. USA. 93:1996;5185-5190.
57. Holms W. H. The central metabolic pathways of Escherichia coli: Relationship between flux and control at a branch point, efficiency of conversion to biomass, and excretion of acetate. Curr. Top. Cell. Regul. 28:1986;69-105.
58. Holms W. H. Metabolic flux analysis. Applied Microbial Physiology. A Practical Approach. 1997;Oxford Univ. Press, New York. p. 213-248.
59. Horwitz M. S. Adenoviruses. Fields B. N. Fields Virology. 1996;2149-2171 Lippincott-Raven, Philadelphia.
60. Jones K. L., Keasling J. D. Construction and characterization of F plasmid-based expression vectors. Biotechnol. Bioeng. 59:1998;659-665.
61. Kacser H., Burns J. A. The control of flux. Symp. Soc. Exp. Biol. 27:1973;65-104.
62. Kafri T., van Praag H., Ouyang L., Gage F. H. M., Verma I. M. A packaging cell line for lentivirus vectors. J. Virol. 73:1999;576-584.
63. Kay M. A., Liu D., Hoogerbrugge P. M. Gene therapy. Proc. Natl. Acad. Sci. USA. 94:1997;12744-12746.
64. Kerem B. S., Rommens J. M., Buchanan J. A. Identification of the cystic fibrosis gene: Genetic analysis. Science. 245:1989;1073-1080.
65. Lachmann R. H., Efstathiou S. The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Mol. Med. Today. 3:1997;404-411.
66. Lauffenburger D. A., Linderman J. J. Receptors, Models for Binding, Trafficking, and Signaling. 1993;Oxford Univ. Press, New York.
67. Lee K. H., Harrington M. G., Bailey J. E. Two-dimensional electrophoresis of proteins as a tool in the metabolic engineering of cell cycle regulation. Biotechnol. Bioeng. 50:1996;336-340.
68. Lee R. J., Huang L. Lipidic vector systems for gene transfer. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;173-206.
69. Levine F., Leibowitz G. Toward gene therapy of diabetes mellitus. Mol. Med. Today. 5:1999;165-171.
70. Liao J. C., Delgado J. Flux calculation using metabolic control constraints. Biotechnol. Prog. 14:1998;554-560.
71. Lindemann D., Patriquin E., Feng S., Mulligan R. C. Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol. Med. Today. 3:1997;466-476.
72. Lockhart D. J., Dong H., Byrne M. C., Follettie M. T., Gallo M. V., Chee M. S., Mittman M., Wang C., Kobayahi M., Horton H., Brown E. L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 14:1996;1675-1680.
73. Marshall E. Gene therapy's growing pains. Science. 269:1995;1050-1055.
74. Mendes P., Kell D. B. Non-linear optimization of biochemical pathways: Applications to metabolic engineering and parameter estimation. Bioinformatics. 14:1998;869-883.
75. Middleton P. G., Alton E. W. F. W. Gene therapy for cystic fibrosis: Which postman, which box? Thorax. 53:1998;197-199.
76. Mulligan R. C. The basic science of gene therapy. Science. 260:1993;926-932.
77. Nielsen J. Metabolic engineering: Techniques for analysis of targets for genetic manipulations. Biotechnol. Bioeng. 58:1998;125-132.
78. Nielsen L. L., Maneval D. C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5:1998;52-63.
79. NIH/ORDA, 1998, Human gene therapy protocols, www.nih.gov/od/orda/protocols.htm.
80. Norman J. A., Hobart P., Manthorpe M., Felgner P., Wheeler C. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine. 15:1997;801-803.
81. Paredes C., Prats E., Cairo J. J., Azorin F., Cornudella L., Godia F. Modification of glucose and glutamine metabolism in hybridoma cells through metabolic engineering. Cytotechnology. 30:1999;85-93.
82. Puttaraju M., Jamison S. F., Mansfield S. G., Garcia-Blanco M. A., Mitchell L. G. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nature Biotechnol. 17:1999;246-252.
83. Rychaudhuri S., Rock K. L. Fully mobilizing host defense: Building better vaccines. Nature Biotechnol. 16:1998;1025-1029.
84. Saizieu A., Certa U., Warringtion J., Gray C., Keck W., Mous J. Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. Nature Biotechnol. 16:1998;45-48.
85. Schilling C. H., Edwards J. S., Palsson B. O. Toward metabolic phenomics: Analysis of genomic data using flux balances. Biotechnol. Prog. 15:1999a;288-295.
86. Schilling C. H., Schuster S., Palsson B. O., Heinrich R. Metabolic pathway analysis: Basic concepts and scientific applications in the post-genomic era. Biotechnol. Prog. 15:1999b;296-303.
87. Shaughnessy E., Lu D., Chatterjee S., Wong K. K. Parvoviral vectors for the gene therapy of cancer. Semin. Oncol. 23:1996;159-171.
88. Shenk T. Adenoviridae: The viruses and their replication. Fields B. N. Fields Virology. 1996;2111-2148 Lippincott-Raven, Philadelphia.
89. Shi H., Nikawa J., Shimizu K. Effect of modifying metabolic network on poly-3-hydroxybutyrate biosynthesis in recombinant Escherichia coli. J. Biosci. Bioeng. 87:1999;666-677.
90. Slapak C. A., Kufe D. W. Principles of cancer therapy. Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L., Hauser S. L., Longo D. L. Harrison's Principles of Internal Medicine. 1998;523-537 McGraw-Hill, New York.
91. Sokol L. D., Gewirtz A. M. Gene therapy: Basic concepts and recent advances. Crit. Rev. Eukaryotic Gene Expr. 6:1996;29-57.
92. Stephanopoulos G. Metabolic fluxes and metabolic engineering. Metab. Eng. 1:1999;1-11.
93. Stephanopoulos G. N., Aristidou A. A., Nielsen J. Metabolic Engineering, Principles and Methodologies. 1998;Academic Press, San Diego. p. 461-533.
94. Stephanopoulos G., Vallino J. J. Network rigidity and metabolic engineering in metabolite overproduction. Science. 252:1991;1675-1681.
95. Sutter G., Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Brown F. Developments in Biological Standardization. 1995;195-200 Karger, Basel.
96. Tang D. C., Dewit M., Johnston S. A. Genetic immunization is a simple method for eliciting an immune response. Nature (London). 356:1992;152-154.
97. Treacy E., Childs B., Scriver C. R. Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison. Am. J. Hum. Genet. 56:1995;359-367.
98. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
99. Valle D. Treatment and prevention of genetic disease. Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L., Hauser S. L., Longo D. L. Harrison's Principles of Internal Medicine. 1998;403-409 McGraw-Hill, New York.
100. Varma A., Palsson B. O. Metabolic flux balancing: Basic concepts, scientific and practical use. Bio/Technology. 12:1994;994-998.
101. Varma A., Boesch B. W., Palsson B. O. Biochemical production capabilities of Escherichia coli. Biotechnol. Bioeng. 42:1993a;59-73.
102. Varma A., Boesch B. W., Palsson B. O. Stoichiometric interpretation of Escherichia coli glucose catabolism under various oxygenation rates. Appl. Environ. Microbiol. 59:1993b;2465-2473.
103. Varner J., Ramkrishna D. Metabolic engineering from a cybernetic perspective. Biotechnol. Prog. 15:1999;407-438.
104. Verpoorte R., van der Heijden R., ten Hoopen H. J. G., Memelink J. Metabolic engineering of plant secondary metabolite pathways for the production of fine chemicals. Biotechnol. Lett. 21:1999;467-479.
105. Vinyals A., Peinado M. A., Gonzalez-Garrigues M., Monzo M., Bonfil R. D., Fabra A. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther. 6:1999;22-33.
106. Vogelstein B., Kinzler K. W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
107. Wagner J. A., Gardner P. Toward cystic fibrosis gene therapy. Annu. Rev. Med. 48:1997;203-216.
108. Wagner R. W., Matteucci M. D., Grant D., Huang T., Froehler B. C. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnol. 14:1996;840-844.
109. Wang Y., DeMayo F. J., Tsai S. Y., O'Malley B. W. Ligand-inducible and liver-specific target gene expression in transgenic mice. Nature Biotechnol. 15:1997;239-243.
110. Welsh M. J., Smith A. E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73:1993;1251-1254.
111. Wolff J. A., Malone R. W., Williams P., Chong W., Acsadi G., Jani A., Felgner P. L. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
112. Wu H., Wade M., Krall L., Grisham J., Xiong Y., Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development, and regeneration. Genes Dev. 10:1996;245-260.
113. Yeh P., Perricaudet M. Advances in adenoviral vectors: From genetic engineering to their biology. FASEB J. 11:1997;615-623.
114. Young N. S. Parvoviruses. Fields B. N. Fields Virology. 1996;2199-2220 Lippincott-Raven, Philadelphia.
115. Zupke C., Stephanopoulos G. Modeling of isotope distributions and intracellular fluxes in metabolic networks using atom mapping matrices. Biotechnol. Prog. 10:1994;489-498.